Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Last trade$1.03
Day change-$0.065 (-5.96%)
Day range$0.976 – $1.14
Volume231,115
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.78M
Price / earnings
—
Price / book
1.43×
Price / sales
117.76×
EV / sales
13.33×
EV / EBITDA
-0.08×
Profitability
Earnings per share
-$1.35
Return on assets
-132.59%
Return on equity
-177.35%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.69×
Quick ratio
3.69×
Cash ratio
3.5×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.32M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LSTA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$100K
$0
$70K
$0
$1M
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$100K
$0
$70K
$0
$1M
$0
Selling, general and administrative
$3.41M
$3.74M
$2.05M
$2.46M
$2.69M
$3.25M
$3M
$2.79M
Research and development
$584K
$1.2M
$1.13M
$1.96M
$2.25M
$2.6M
$2.95M
$2.54M
Total operating expenses
$3.99M
$4.94M
$3.18M
$4.41M
$4.94M
$5.85M
$5.95M
$5.34M
Operating income
-$3.99M
-$4.94M
-$3.08M
-$4.41M
-$4.87M
-$5.85M
-$4.95M
-$5.34M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.93M
-$4.88M
-$2.95M
-$4.25M
-$4.66M
-$5.69M
-$4.61M
-$4.93M
Income taxes
$0
-$387K
$0
$0
$0
-$962K
$0
$0
Net income
-$2.93M
-$4.49M
-$2.95M
-$4.25M
-$4.66M
-$4.72M
-$4.61M
-$4.93M
Net income attributable to common shareholders
-$2.93M
-$4.49M
-$2.95M
-$4.25M
-$4.66M
-$4.72M
-$4.61M
-$4.93M
EBITDA
-$3.99M
-$4.94M
-$3.06M
-$4.37M
-$4.82M
-$5.8M
-$4.91M
-$5.29M
Basic earnings per share
-$0.32
-$0.50
-$0.34
-$0.49
-$0.54
-$0.55
-$0.55
-$0.59
Diluted earnings per share
-$0.32
-$0.50
-$0.34
-$0.49
-$0.54
-$0.55
-$0.55
-$0.59
Recent news
Company coverage with links to the original publishers.
Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced that MAR001, a monoclonal antibody targeting ANGPTL4, met all objectives in Phase 2b TYDAL-TIMI 78 trial for severe hypertriglyceridemia treatment. The drug achieved placebo-adjusted triglyceride reductions of 39.1%-45.5% across doses at Week 12, with up to 72.2% reduction in participants with baseline triglycerides ≥500 mg/dL. The drug demonstrated a favorable safety profile with no worsening of HbA1c. Results were presented at AHA 2026 and published in The New England Journal of Medicine.
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. Baldwin Group (BWIN) is being sold for $32.50 per share, Lisata Therapeutics (LSTA) for $4.00 per share plus contingent value rights, and ACV for $10.50 per share. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.
Kuva Labs Inc. has commenced a tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus contingent value rights worth up to $3.00 per share based on achievement of clinical milestones. The transaction values Lisata at a premium to historical market prices and is expected to close in Q3 2026. Lisata's Board unanimously recommends stockholders tender their shares.
Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.
Monteverde & Associates PC is investigating four merger transactions: Talkspace's sale to Universal Health Services at $5.25/share, Lisata Therapeutics' sale to Kuva Labs at $4.00/share plus contingent value rights, National Storage Affiliates Trust's sale to Public Storage at 0.14 shares per unit, and KalVista Pharmaceuticals' sale to Chiesi Group at $27.00/share. The firm is seeking shareholders to determine if the proposed deal terms are fair.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.